British Lung Foundation
AstraZeneca opens new global strategic R&D centre in US
The new centre will be home to nearly 2,000 world-class researchers and scientists
Chiesi UK and Ireland supports NHS workforce to address COPD diagnosis backlog
An estimated two million people in the UK are living with undiagnosed chronic obstructive pulmonary disease
AstraZeneca and Daiichi Sankyo to collaborate with Summit Therapeutics
This builds on a recently announced clinical collaboration between AstraZeneca and Summit to advance cancer treatments
AstraZeneca’s Trixeo gets EU approval for asthma maintenance treatment
Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history
AstraZeneca’s Tagrisso shows eight-year landmark survival in early-stage EGFR-mutated lung cancer
The results from a global phase 3 trial show the longest survival data ever reported in this setting
Gilead opens new research centre bringing together oncology, inflammation and research data science teams
The centre in California supports the company’s $32bn US investment
AstraZeneca and Daiichi Sankyo’s Enhertu plus pertuzumab approved in EU as first-line treatment for breast cancer
This is the first new regimen in more than a decade for first-line treatment for this type of breast cancer
NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia
The treatments are for eligible adults in England and Wales
AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma
Asthma affects over 360 million people worldwide, including over 40 million people in Europe
AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical
The company will gain a novel oral treatment for lung cancer
AstraZeneca reports positive phase 3 data for tozorakimab in COPD
COPD affects nearly 400 million people globally and is the third leading cause of death worldwide
AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers
This is the first and only perioperative immunotherapy approved to treat early gastric cancers